Results of the first UK trial conducted by Professor Anthony Chu and Dr Benedetta Brazzini (Ealing Hospital and The Marylebone Clinic)

The efficacy trial was conducted between September 1016 and September 2017. Patients were assessed during three visits over an eight week period at Ealing Hospital, west London, and the Marylebone Clinic, Harley Street, using the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index DLQI).

The more widespread and severe a person’s symptoms, the higher their PASI score will be. The DLQI assesses the impact of a dermatological condition on a person’s well-being, where 30 indicates a high impact and a low level of well-being, and zero represents no impact and a high state of well-being.

There were 20 patients, 14 male, six female. Ages ranged from 11 to 79, with an average of 43.5.

 PASI

Improvement of 0-25%: 3 patients (15%)

Improvement of 26-50%: 5 patients (25%)

Improvement of 51-75%: 8 patients (40%)

Improvement of 76-100%: 4 patients (20%)

 

DLQI

 

Improvement of 0-25%: 4 patients (20%)

Improvement of 26-50%: 3 patients (15%)

Improvement of 51-75%: 4 patients (20%)

Improvement of 76-100%: 9 patients (45%)

 

 

                  T 0

T 1-4 weeks

T 2-8 weeks

Patient

comments

PASI         11.1

DLQI         11

5.2

1

4

1

S1

 

PASI         18.9

DLQI        11

14

9

10.5

4

S2

 

PASI         10

DLQI        11

10

11

10

11

S3

No improvement had to start biologics

PASI        5.2

DLQI       14

5.2

15

3.6

12

S4

 

PASI        3.6

DLQI       8

2

6

1.4

2

S5

 

PASI        6

DLQI       11

5

8

2

1

S6

 

PASI        6

DLQI       8

5

6

3

3

S7

 

 

 

PASI        11.1

DLQI       11

3.6

1

1

0

S8

 

PASI        3

DLQI       6

1.4

6

0

0

S9

 

PASI        5.2

DLQI        8

3.5

6

2

1

S10

 

PASI        7.8

DLQI       20

4.7

9

1

0

S11

 

PASI        13

DLQI        8

Dropped out because of no improvement

 

S12

Had to start systemics MTX

PASI        13.6

DLQI       17

10

13

2

1

S13

 

PASI        2.1

DLQI       7

1

1

 

1

1

S14

 

PASI        13.8

DLQI       18

11.5

15

8

10

S15

 

PASI        4.6

DLQI       16

3

10

2

8

S16

 

PASI        3.8

DLQI       16

6

5

2.8

7

S17

 

PASI        5.2

DLQI       4

4.8

4

4

3

S18

 

PASI        3

DLQI       2

2

1

1.2

1

S19

 

PASI      19.5

DLQI      18

8.7

8

4.9 *

3*

S20

*Patient’s final readings were delayed by a week because of unconnected illness